Leukemia Clinical Trial
Official title:
PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver
tumor-killing substances to them, without harming normal cells. Drugs used in chemotherapy
use different ways to stop cancer cells from dividing so they stop growing or die. Combining
chemotherapy with monoclonal antibody therapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus monoclonal antibody
therapy in treating patients with acute promyelocytic leukemia in remission.
OBJECTIVES: I. Evaluate the antileukemic effects of humanized anti-CD33 monoclonal antibody
M195 (HuM195) against minimal residual disease in patients with acute promyelocytic leukemia
(APL) by using a reverse transcription-polymerase chain reaction for the mutated retinoic
acid receptor-alpha to detect changes in minimal residual disease. II. Assess the disease
free and overall survival of patients with APL receiving HuM195 for minimal residual
disease. III. Evaluate the safety and toxicity of HuM195 in these patients. IV. Evaluate
whether HuM195 elicits a human anti-human antibody response, including anti-idiotype
antibody responses, in patients with APL.
OUTLINE: Patients continue retinoid therapy until 30 days after documentation of clinical
complete remission. Patients begin treatment within 10 days of documentation of clinical
complete remission, or after RT-PCR-confirmed molecular relapse, or 3-6 weeks after
chemotherapy. Patients receive HuM195 IV over 60 minutes twice a week for 6 doses. Patients
with unacceptable toxicity, in first complete remission, or ineligible for bone marrow
transplant (BMT) proceed to the next regimen. Patients receive idarubicin IV over 15 minutes
on days 1-3 and cytarabine IV continuously over days 1-5. Patients then receive 2 more
courses, given at 4-6 week intervals, consisting of idarubicin IV over 15 minutes on days
1-2 and cytarabine IV continuously on days 1-4. Patients begin maintenance therapy after
toxicity resolves or 1 week after the last dose of HuM195. This consists of HuM195 IV over
60 minutes for 2 doses (72-96 hours apart). Treatment repeats once a month for 6 courses.
Patients who have an initial molecular response but are positive on the RT-PCR assay, or who
achieve complete remission following clinical relapse of disease during treatment are
eligible for retreatment. Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 14-40 patients will be accrued for this study over 2-3 years.
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
| Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
| Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
| Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |